SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Jay Ferro, EVP, CIO, CPO & CTO, Clario
Drug Development
SCOPE Summit 2025 Key Takeaways: A Look Inside, Outside and Beyond the Cybersecurity Wall
Jay Ferro, EVP, CIO, CPO & CTO at Clario discusses safety, trust and what keeps him up at night.
February 13, 2025
 · 
1 min read
 · 
Lori Ellis
Illustration of hands holding puzzle pieces to fit them together
Career Advice
Career Coach: How to Recover From a Bad Interview
Plus, how to use your network effectively and create job opportunities before they exist
February 13, 2025
 · 
5 min read
 · 
Carina Clingman
Illustration of robot using paper shredder to destroy employee application
Career Advice
Job Ghosting, Ghost Jobs Top Job Hunt Complaints, BioSpace Finds
A BioSpace LinkedIn poll found that job ghosting and ghost jobs are the biggest pet peeves for applicants now. Recruitment Manager Greg Clouse offers advice on dealing with them.
February 13, 2025
 · 
5 min read
 · 
Angela Gabriel
Art collage, hands and falling coins in orange circle. Modern design of finance and business.
Neuropsychiatric disorders
Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche
Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
February 13, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Job Trends
2024 Q4 Job Market Report: Biopharma Job Postings Slowed as Layoffs Continued
Year-over-year BioSpace data show there were fewer job postings live on the website in the fourth quarter of 2024, and the decrease was higher than the third quarter’s drop.
February 12, 2025
 · 
3 min read
 · 
Angela Gabriel
Achieve goal concept art collage. Rising arrow chart and halftone hand pointing to center of dartboard. Business goal, achieve targets, success. Trendy modern retro vector illustration
Earnings
With Leqembi Sales Trending Up, Biogen Gets Down to Brass Tacks: It Works
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s disease. With patients now hitting the 18-month mark of treatment, the conversation is finally shifting to efficacy.
February 12, 2025
 · 
3 min read
 · 
Annalee Armstrong
AbbVie's office in South San Francisco, California
Deals
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B
The pharma giant inked its third T cell engager deal of 2025 Wednesday—this time with Xilio Therapeutics for tumor-activated immunotherapies.
February 12, 2025
 · 
1 min read
 · 
Kate Goodwin
A human hand showing dollar golden coins in the jar with a colored background. Collage Art of finance
Funding
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion body myositis through clinical trials. Now, Abcuro is eyeing a regulatory submission and potential launch.
February 12, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.
Collaboration
Biogen Taps Royalty Pharma for $250M to Power Phase III Lupus Program
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the company’s forecasted dip in 2025 revenues.
February 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS